PURPOSE: To develop and test a molecular imaging approach that uses ultrasonography (US) and a clinically translatable dual-targeted (P- and E-selectin) contrast agent (MBSelectin) in the quantification of inflammation at the molecular level and to quantitatively correlate selectin-targeted US with fluorodeoxyglucose (FDG) combined positron emission tomography (PET) and computed tomography (CT) in terms of visualization and quantification of different levels of inflammation in a murine acute colitis model. MATERIALS AND METHODS: Animal studies were approved by the Institutional Administrative Panel on Laboratory Animal Care at Stanford University. MBSelectin was developed by covalently binding an analog of the naturally occurring binding ligand P-selectin glycoprotein ligand 1 fused to a human fragment crystallizable(or Fc) domain onto the lipid shell of perfluorobutane and nitrogen-containing MBs. Binding specificity of MBSelectin was assessed in vitro with a flow chamber assay and in vivo with a chemically induced acute colitis murine model. US signal was quantitatively correlated with FDG uptake at PET/CT and histologic grade. Statistical analysis was performed with the Student t test, analysis of variance, and Pearson correlation analysis. RESULTS: MBSelectin showed strong attachment to both human and mouse P- and E-selectin compared with MBControl in vitro (P ≤ .002). In vivo, US signal was significantly increased (P < .001) in mice with acute colitis (173.8 arbitrary units [au] ± 134.8 [standard deviation]) compared with control mice (5.0 au ± 4.5). US imaging signal strongly correlated with FDG uptake on PET/CT images (ρ = 0.89, P < .001). Ex vivo analysis enabled confirmation of inflammation in mice with acute colitis and high expression levels of P- and E-selectin in mucosal capillaries (P = .014). CONCLUSION: US with MBSelectin specifically enables detection and quantification of inflammation in a murine acute colitis model, leveraging the natural pathway of leukocyte recruitment in inflammatory tissue. US imaging with MBSelectin correlates well with FDG uptake at PET/CT imaging.
PURPOSE: To develop and test a molecular imaging approach that uses ultrasonography (US) and a clinically translatable dual-targeted (P- and E-selectin) contrast agent (MBSelectin) in the quantification of inflammation at the molecular level and to quantitatively correlate selectin-targeted US with fluorodeoxyglucose (FDG) combined positron emission tomography (PET) and computed tomography (CT) in terms of visualization and quantification of different levels of inflammation in a murineacute colitis model. MATERIALS AND METHODS: Animal studies were approved by the Institutional Administrative Panel on Laboratory Animal Care at Stanford University. MBSelectin was developed by covalently binding an analog of the naturally occurring binding ligand P-selectin glycoprotein ligand 1 fused to a human fragment crystallizable(or Fc) domain onto the lipid shell of perfluorobutane and nitrogen-containing MBs. Binding specificity of MBSelectin was assessed in vitro with a flow chamber assay and in vivo with a chemically induced acute colitismurine model. US signal was quantitatively correlated with FDG uptake at PET/CT and histologic grade. Statistical analysis was performed with the Student t test, analysis of variance, and Pearson correlation analysis. RESULTS:MBSelectin showed strong attachment to both human and mouseP- and E-selectin compared with MBControl in vitro (P ≤ .002). In vivo, US signal was significantly increased (P < .001) in mice with acute colitis (173.8 arbitrary units [au] ± 134.8 [standard deviation]) compared with control mice (5.0 au ± 4.5). US imaging signal strongly correlated with FDG uptake on PET/CT images (ρ = 0.89, P < .001). Ex vivo analysis enabled confirmation of inflammation in mice with acute colitis and high expression levels of P- and E-selectin in mucosal capillaries (P = .014). CONCLUSION: US with MBSelectin specifically enables detection and quantification of inflammation in a murineacute colitis model, leveraging the natural pathway of leukocyte recruitment in inflammatory tissue. US imaging with MBSelectin correlates well with FDG uptake at PET/CT imaging.
Authors: Chong Shen; Gert de Hertogh; Dominique M A Bullens; Gert Van Assche; Karel Geboes; Paul Rutgeerts; Jan L Ceuppens Journal: Inflamm Bowel Dis Date: 2007-03 Impact factor: 5.325
Authors: K E Norman; A G Katopodis; G Thoma; F Kolbinger; A E Hicks; M J Cotter; A G Pockley; P G Hellewell Journal: Blood Date: 2000-11-15 Impact factor: 22.113
Authors: Heather A Jacene; Philip Ginsburg; John Kwon; Geoffrey C Nguyen; Elizabeth A Montgomery; Theodore M Bayless; Richard L Wahl Journal: J Nucl Med Date: 2009-10-16 Impact factor: 10.057
Authors: Sarah Brewer; Michael McPherson; Daisuke Fujiwara; Olga Turovskaya; David Ziring; Ling Chen; Hidetoshi Takedatsu; Stephan R Targan; Bo Wei; Jonathan Braun Journal: Gastroenterology Date: 2008-07-17 Impact factor: 22.682
Authors: Huaijun Wang; Stephen A Felt; Ismayil Guracar; Valentina Taviani; Jianhua Zhou; Rosa Maria Silveira Sigrist; Huiping Zhang; Joy Liau; José G Vilches-Moure; Lu Tian; Yamil Saenz; Thierry Bettinger; Brian A Hargreaves; Amelie M Lutz; Jürgen K Willmann Journal: Eur Radiol Date: 2017-11-23 Impact factor: 5.315
Authors: Parakkal Deepak; Amy B Kolbe; Jeff L Fidler; Joel G Fletcher; John M Knudsen; David H Bruining Journal: Gastroenterol Hepatol (N Y) Date: 2016-04
Authors: Igor Spivak; Anne Rix; Georg Schmitz; Stanley Fokong; Olga Iranzo; Wiltrud Lederle; Fabian Kiessling Journal: Mol Imaging Biol Date: 2016-04 Impact factor: 3.488
Authors: Huaijun Wang; Stephen A Felt; Steven Machtaler; Ismayil Guracar; Richard Luong; Thierry Bettinger; Lu Tian; Amelie M Lutz; Jürgen K Willmann Journal: Radiology Date: 2015-05-12 Impact factor: 11.105